NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Open in Screener

TECX

Tectonic Therapeutic Inc

May 02 • 04:00PM ET

21.75

Dollar change +2.09
Percentage change 10.61	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN AMGN GILD BIIB BMRN INCY EXEL NBIX RGEN

| Held by: VTI VXF IBB IWC AVSC DFAS BBC DFAC DFUS DFAU

Index	-	P/E	-	EPS (ttm)	-8.20	Insider Own	43.43%	Shs Outstand	14.86M	Perf Week	3.11%
Market Cap	405.98M	Forward P/E	-	EPS next Y	-4.84	Insider Trans	13.05%	Shs Float	10.56M	Perf Month	21.55%
Income	-49.57M	PEG	-	EPS next Q	-1.09	Inst Own	39.61%	Short Float	14.27%	Perf Quarter	-59.84%
Sales	0.00M	P/S	-	EPS this Y	34.55%	Inst Trans	5.08%	Short Ratio	5.70	Perf Half Y	-46.94%
Book/sh	9.48	P/B	2.29	EPS next Y	-8.19%	ROA	-39.03%	Short Interest	1.51M	Perf Year	52.28%
Cash/sh	7.57	P/C	2.87	EPS next 5Y	3.62%	ROE	-42.09%	52W Range	13.70 - 61.07	Perf YTD	-52.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	26.54%	ROI	-35.08%	52W High	-64.39%	Beta	1.50
Dividend TTM	-	Quick Ratio	12.65	Sales past 5Y	0.00%	Gross Margin	-	52W Low	58.72%	ATR (14)	1.84
Dividend Ex-Date	-	Current Ratio	12.65	EPS Y/Y TTM	-343.40%	Oper. Margin	-	RSI (14)	56.27	Volatility	8.36% 9.86%
Employees	51	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	74.25
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	64.57%	Payout	-	Rel Volume	1.17	Prev Close	19.66
Sales Surprise	-	EPS Surprise	39.42%	Sales Q/Q	-	Earnings	Mar 20 AMC	Avg Volume	264.29K	Price	21.75
SMA20	17.87%	SMA50	4.20%	SMA200	-28.40%	Trades		Volume	309,496	Change	10.61%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-21-25	Initiated	Mizuho	Outperform	$51
Nov-20-24	Initiated	Raymond James	Outperform	$65
Aug-22-24	Initiated	Wells Fargo	Overweight	$55
Jun-26-24	Initiated	Piper Sandler	Overweight
Jun-24-24	Initiated	TD Cowen	Buy
Dec-18-23	Downgrade	Mizuho	Buy → Neutral
Jan-05-22	Downgrade	BTIG Research	Buy → Neutral
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$24 → $7
Jun-15-21	Initiated	BTIG Research	Buy	$23
May-27-21	Initiated	Needham	Buy	$28
Mar-09-21	Initiated	Barclays	Overweight	$23
Mar-02-21	Initiated	Stifel	Hold	$14
Nov-11-20	Initiated	Berenberg	Buy
Mar-31-20	Downgrade	H.C. Wainwright	Buy → Neutral	$13
Jun-27-19	Initiated	Mizuho	Buy	$28
Apr-05-19	Initiated	Janney	Buy
Oct-10-18	Initiated	Guggenheim	Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$47 → $40
Sep-17-18	Initiated	H.C. Wainwright	Buy	$47
Jul-16-18	Initiated	Wells Fargo	Outperform	$40

Show Previous Ratings

May-01-25 05:59AM	TipRanks Perfect 10 Picks: 2 Top-Scoring Stocks Earning Wall Streets Seal of Approval (TipRanks) -5.75%
Apr-23-25 05:51AM	Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF (Seeking Alpha)
Apr-15-25 08:00AM	Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025 (GlobeNewswire)
Mar-20-25 04:01PM	Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-04-25 08:26PM	Is Tectonic Therapeutic, Inc. (TECX) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
08:00AM	Loading…
Feb-20-25 08:00AM	Tectonic Therapeutic to Participate in March Investor Conferences (GlobeNewswire)
Feb-03-25 06:30AM	Tectonic Announces $185 Million Private Placement (GlobeNewswire) -6.52%
Jan-30-25 06:30AM	Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF (GlobeNewswire) +113.22%
Dec-03-24 04:01PM	Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024 (GlobeNewswire)
Nov-26-24 04:01PM	Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-12-24 11:01PM	Tectonic Therapeutic Inc. Reports Q3 2024 Results (TipRanks)
Nov-11-24 05:00AM	Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein (GlobeNewswire)
Nov-07-24 04:01PM	Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-22-24 04:01PM	Tectonic Therapeutic to Present Phase 1a Data at AHA 2024 (GlobeNewswire)
Sep-19-24 04:01PM	Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 (GlobeNewswire)
04:01PM	Loading…
Aug-20-24 04:01PM	Tectonic Therapeutic to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-24 04:01PM	Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +5.23%
Jul-30-24 04:01PM	Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45 (GlobeNewswire)
Jun-20-24 04:01PM	Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million (Business Wire)
09:47AM	PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML (InvestorPlace)
08:26AM	Why Is Avrobio (AVRO) Stock Moving Today? (InvestorPlace)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-15-24 11:27AM	Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing (MT Newswires) +6.20%
May-13-24 09:53AM	AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024 (InvestorPlace) +9.76%
Feb-27-24 10:50AM	Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm (PR Newswire)
Feb-01-24 02:25PM	Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm (PR Newswire)
Jan-31-24 10:40AM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TAST, AVRO, CALB (GlobeNewswire) +9.57%
06:42AM	Avrobios road ends in reverse merger with Tim Springer-backed startup (BioPharma Dive)
Jan-30-24 02:52PM	Avrobio's corporate tremor attracts Tectonic for reverse merger (FierceBiotech.com) -16.06%
02:38PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCAL (PR Newswire)
08:00AM	Loading…
08:00AM	AVROBIO and Tectonic Therapeutic Announce Merger (Business Wire)
Nov-08-23 09:40AM	Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-23-23 09:40AM	Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-06-23 09:40AM	Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-13-23 07:08AM	AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46% (Zacks)
Jul-12-23 07:00AM	AVROBIO to Explore Strategic Alternatives (Business Wire) +45.96%
Jun-12-23 07:00AM	AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million (Business Wire)
May-22-23 07:00AM	AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million (Business Wire) +69.01%
May-18-23 02:53PM	Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months (Benzinga) +45.33%
07:00AM	AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting (Business Wire)
May-11-23 07:00AM	AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-01-23 07:30AM	AVROBIO Announces Leadership Transition (Business Wire) -15.99%
Mar-23-23 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update (Business Wire) -27.64%
Mar-03-23 07:00AM	AVROBIO to Participate in Cowens 43rd Annual Health Care Conference (Business Wire)
Feb-09-23 07:00AM	AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium 2023 (Business Wire) +7.69%
Jan-05-23 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-07-22 07:30AM	AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy (Business Wire) -6.96%
Nov-17-22 07:00AM	AVROBIO to Share Comprehensive Gaucher Disease Program Update (Business Wire) +5.40%
Nov-08-22 07:00AM	AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-07-22 07:00AM	AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit (Business Wire)
Nov-03-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-27-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire)
Oct-25-22 07:00AM	AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis (Business Wire)
Oct-18-22 07:00AM	AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire) +12.37%
Oct-11-22 07:00AM	AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development (Business Wire)
Oct-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-27-22 07:00AM	AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress (Business Wire) -10.23%
Sep-20-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis (Business Wire)
Sep-14-22 07:28AM	AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial (Business Wire)
Sep-08-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-22 07:00AM	AVROBIO to Participate in Four Upcoming Investor Conferences in September (Business Wire)
Aug-09-22 07:00AM	AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-22 07:00AM	AVROBIO to Participate in Two Upcoming Investor Conferences in August (Business Wire)
Jul-13-22 07:00AM	AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome (Business Wire)
Jul-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.47%
May-18-22 03:12PM	AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study (Zacks) -8.57%
12:41PM	Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study (Benzinga)
07:00AM	AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (Business Wire)
May-17-22 12:15PM	AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study (Benzinga)
07:00AM	AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures (Business Wire)
May-16-22 07:00AM	AVROBIO to Present at the H.C. Wainwright Global Investment Conference (Business Wire)
May-10-22 07:00AM	AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire)
May-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-03-22 07:00AM	AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting (Business Wire)
Apr-06-22 12:36PM	bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn (Zacks)
07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-05-22 12:54PM	Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study (Zacks)
07:00AM	AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-17-22 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update (Business Wire) +8.33%
Mar-01-22 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences in March (Business Wire)
Feb-21-22 12:14PM	2 Net Current Asset Value Stocks to Consider (GuruFocus.com)
Feb-09-22 12:55PM	After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data (Benzinga) -6.25%
07:00AM	AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis (Business Wire)
Feb-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-03-22 10:00AM	Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks (Zacks)
Feb-01-22 07:00AM	AVROBIO Announces the Appointment of Sean OBryan as Chief Regulatory Officer (Business Wire)
Jan-28-22 07:00AM	AVROBIO to Present at Cowens 2nd Annual Genetic Medicines Summit (Business Wire) +6.32%
Jan-27-22 07:00AM	AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium 2022 (Business Wire) -5.43%
Jan-25-22 10:00AM	Bears are Losing Control Over AVROBIO, Inc. (AVRO), Here's Why It's a 'Buy' Now (Zacks)
Jan-07-22 10:00AM	Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 44.1% in 4 Weeks (Zacks)
Jan-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-22 02:28PM	AvroBio shares plunge after company halts development of Fabry drug (American City Business Journals) -36.63%
09:07AM	Wedbush Says Avrobio Shares Still Undervalued Despite 33% Fall (Investing.com)
07:57AM	Why Avrobio's Shares Are Plunging Today (Benzinga)
07:00AM	AVROBIO Reprioritizes Pipeline Programs (Business Wire)
Dec-07-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.67%
Dec-04-21 06:25AM	Is AVROBIO (NASDAQ:AVRO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-24-21 07:00AM	AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1 (Business Wire)
Nov-09-21 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences in November (Business Wire)

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	16.31	53,706	875,945	1,503,358	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	16.73	45,858	767,204	1,449,652	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	14.76	21,071	311,020	1,403,794	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	16.31	9,478	154,586	4,334,846	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	16.73	8,092	135,379	4,325,368	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	14.76	3,718	54,880	4,317,276	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 07 '25	Buy	17.10	412,500	7,053,750	1,382,723	Apr 09 05:38 PM
SPRINGER TIMOTHY A	Director	Apr 07 '25	Buy	17.10	87,500	1,496,250	4,313,558	Apr 09 05:38 PM
MCGUIRE TERRANCE	Director	Apr 07 '25	Sale	17.10	500,000	8,550,000	573,062	Apr 07 05:02 PM
SPRINGER TIMOTHY A	Director	Feb 05 '25	Buy	50.00	660,000	33,000,000	970,223	Feb 07 04:21 PM
SPRINGER TIMOTHY A	Director	Feb 05 '25	Buy	54.14	129,294	6,999,977	4,226,058	Feb 07 04:21 PM
Lochner Daniel	Chief Financial Officer	Feb 05 '25	Buy	54.14	4,617	249,964	4,617	Feb 07 04:19 PM
Schwabish Marc	Chief Business Officer	Jan 28 '25	Option Exercise	2.38	2,700	6,426	4,700	Jan 29 04:05 PM
Schwabish Marc	Chief Business Officer	Dec 09 '24	Option Exercise	2.38	2,000	4,760	2,000	Dec 11 04:21 PM
McNamara Peter	Chief Scientific Officer	Dec 03 '24	Option Exercise	2.38	3,500	8,330	14,188	Dec 05 04:32 PM
SPRINGER TIMOTHY A	Director	Oct 22 '24	Buy	33.59	300,000	10,077,000	4,096,764	Oct 24 05:04 PM
SPRINGER TIMOTHY A	Director	Sep 26 '24	Buy	28.82	50,000	1,440,829	3,796,764	Sep 26 06:15 PM
Leonard Braden Michael	10% Owner	May 13 '24	Buy	1.25	469,753	585,546	4,471,380	May 15 11:21 AM
Leonard Braden Michael	10% Owner	May 14 '24	Buy	1.30	296,882	385,947	4,768,262	May 15 11:21 AM

Dollar change +0.43
Percentage change 3.50	%

RNAC Cartesian Therapeutics Inc daily Stock Chart

Peers: ALNY IONS SRPT ARWR PBYI BLUE CRSP EDIT GILD VRTX

| Held by: VTI IWM VXF IWO IBB VTWO IWC SBIO VTWG BBC

Index	RUT	P/E	-	EPS (ttm)	-52.64	Insider Own	67.71%	Shs Outstand	23.90M	Perf Week	7.35%
Market Cap	329.44M	Forward P/E	-	EPS next Y	-3.57	Insider Trans	2.72%	Shs Float	8.37M	Perf Month	-1.93%
Income	-286.59M	PEG	-	EPS next Q	-0.70	Inst Own	20.86%	Short Float	28.47%	Perf Quarter	-34.23%
Sales	47.94M	P/S	6.87	EPS this Y	32.10%	Inst Trans	-2.98%	Short Ratio	25.37	Perf Half Y	-43.18%
Book/sh	0.03	P/B	403.56	EPS next Y	-17.00%	ROA	-102.11%	Short Interest	2.38M	Perf Year	-42.46%
Cash/sh	8.45	P/C	1.50	EPS next 5Y	0.19%	ROE	-938.38%	52W Range	8.85 - 41.87	Perf YTD	-29.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	34.24%	ROI	-2268.56%	52W High	-69.67%	Beta	0.41
Dividend TTM	-	Quick Ratio	10.70	Sales past 5Y	112.90%	Gross Margin	98.05%	52W Low	43.50%	ATR (14)	1.10
Dividend Ex-Date	-	Current Ratio	10.70	EPS Y/Y TTM	-645.78%	Oper. Margin	-109.96%	RSI (14)	51.32	Volatility	7.26% 11.88%
Employees	-	Debt/Eq	19.53	Sales Y/Y TTM	38.82%	Profit Margin	-597.83%	Recom	1.50	Target Price	37.33
Option/Short	Yes / Yes	LT Debt/Eq	15.84	EPS Q/Q	35.44%	Payout	-	Rel Volume	0.70	Prev Close	12.27
Sales Surprise	-523.91%	EPS Surprise	28.86%	Sales Q/Q	-94.09%	Earnings	Mar 13 BMO	Avg Volume	93.92K	Price	12.70
SMA20	12.27%	SMA50	-11.43%	SMA200	-26.06%	Trades		Volume	66,271	Change	3.50%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-24	Initiated	BTIG Research	Buy	$42
Aug-06-24	Initiated	TD Cowen	Buy
Jul-02-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-24	Initiated	Oppenheimer	Outperform	$50
May-24-24	Initiated	Mizuho	Buy	$40
Apr-23-24	Reiterated	H.C. Wainwright	Buy	$2 → $54
Apr-23-24	Initiated	Leerink Partners	Outperform	$39
Aug-18-23	Downgrade	SVB Securities	Outperform → Market Perform	$1
Jun-14-22	Reiterated	Needham	Buy	$6 → $5
Jun-06-22	Initiated	SVB Leerink	Outperform	$7
Jun-15-21	Initiated	BTIG Research	Buy	$10
Jan-26-21	Upgrade	Mizuho	Neutral → Buy	$2.50 → $8
Oct-01-20	Downgrade	William Blair	Outperform → Mkt Perform
Oct-01-20	Downgrade	Mizuho	Buy → Neutral	$2.50
Jun-12-20	Downgrade	Stifel	Buy → Hold
Apr-28-20	Initiated	H.C. Wainwright	Buy	$8
Jan-29-20	Initiated	Cantor Fitzgerald	Overweight	$10
Jan-21-20	Initiated	William Blair	Outperform
Jun-27-18	Initiated	Janney	Buy	$33
Mar-30-17	Reiterated	UBS	Buy	$26

Show Previous Ratings

Today 07:48AM	Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential (Insider Monkey)
May-02-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Apr-08-25 07:00AM	Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial (GlobeNewswire) -5.84%
Apr-02-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Apr-01-25 07:00AM	Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.24%
12:15PM	Loading…
Mar-14-25 12:15PM	Amgen data muddies outlook for Cartesian, says Oppenheimer (TipRanks)
Mar-13-25 07:00AM	Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-06-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
Feb-18-25 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-06-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jan-27-25 07:00AM	Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis (GlobeNewswire)
Jan-13-25 07:00AM	Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases (GlobeNewswire) +8.85%
Jan-07-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Dec-20-24 06:50AM	Cartesian Therapeutics initiated with a Buy at BTIG (TipRanks)
Dec-18-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) -7.59%
06:33AM	Loading…
Dec-04-24 06:33AM	Cartesian Therapeutics Reports Promising Phase 2b Trial Results (TipRanks) +9.56%
Dec-03-24 06:00AM	Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial (GlobeNewswire)
Nov-21-24 07:00AM	Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit (GlobeNewswire)
Nov-14-24 10:01AM	Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 (GuruFocus.com)
Nov-08-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Nov-07-24 07:00AM	Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 09:00AM	Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting (GlobeNewswire)
Oct-15-24 07:00AM	Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting (GlobeNewswire) -5.58%
Oct-04-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) +7.45%
Sep-09-24 07:00AM	Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis (GlobeNewswire)
Sep-06-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire) -7.55%
Sep-03-24 07:00AM	Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 (GlobeNewswire) -6.02%
Aug-26-24 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:00AM	Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.43%
Aug-07-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
04:05PM	Loading…
Jul-08-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jul-03-24 02:25PM	Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates (Zacks) +11.73%
Jul-02-24 04:08PM	Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs (Investor's Business Daily) -35.02%
04:05PM	Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik (GlobeNewswire)
06:31AM	Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus (GlobeNewswire)
06:31AM	Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing (GlobeNewswire)
06:30AM	Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis (GlobeNewswire)
Jun-06-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
May-23-24 12:12PM	Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08 (Zacks)
May-22-24 07:00AM	Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis (GlobeNewswire)
May-13-24 04:30PM	Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire) +15.38%
12:00PM	What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet (Zacks)
May-10-24 03:12PM	Cartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ... (GuruFocus.com)
May-08-24 02:52PM	RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 04:15PM	Cartesian Therapeutics Announces New Employment Inducement Grants (Business Wire) -9.85%
Apr-25-24 09:55AM	Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade (Zacks)
Apr-22-24 04:30PM	Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting (Business Wire) +12.76%
Apr-08-24 09:35AM	Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC) (Zacks)
Apr-04-24 07:30AM	Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
07:00AM	Cartesian Therapeutics Announces New Employment Inducement Grants (Business Wire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey) -5.36% -7.55%
Mar-28-24 04:05PM	Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split (GlobeNewswire) -13.83%
Mar-14-24 09:35AM	Cartesian Therapeutics, Inc. (RNAC) Loses -24.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-07-24 11:51PM	RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -8.04%
07:00AM	Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-06-24 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-05-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
07:00AM	Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland (GlobeNewswire)
Feb-05-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) -9.18% +5.35%
Jan-22-24 09:19AM	Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today? (InvestorPlace)
Jan-08-24 07:10AM	Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity (GlobeNewswire) +5.87%
07:00AM	Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis (GlobeNewswire)
Nov-13-23 08:05AM	Selecta Biosciences Announces Merger with Cartesian Therapeutics (GlobeNewswire) -8.00%
Oct-31-23 04:03PM	Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi (GlobeNewswire) -7.20%
Aug-24-23 06:21AM	The Petri Dish: Selecta gets selective with drug programs; Moderna enters 2nd cancer vaccine collab (American City Business Journals)
Aug-17-23 10:20PM	Q2 2023 Selecta Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:15AM	Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics (GlobeNewswire)
Jul-14-23 07:08AM	Selecta Biosciences, Inc.'s (NASDAQ:SELB) largest shareholders are individual investors with 35% ownership, institutions own 26% (Simply Wall St.)
Jul-13-23 03:00PM	10 Best Revenue Growth Stocks to Buy (Insider Monkey)
Jun-03-23 08:20AM	Selecta Biosciences (NASDAQ:SELB) shareholders are up 22% this past week, but still in the red over the last five years (Simply Wall St.)
May-31-23 07:00AM	Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology (GlobeNewswire)
May-09-23 06:06AM	Newsflash: Selecta Biosciences, Inc. (NASDAQ:SELB) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
May-04-23 08:45AM	Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.96%
07:30AM	Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-23 04:05PM	Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update (GlobeNewswire) -5.04%
Apr-18-23 06:11AM	Investors Holding Back On Selecta Biosciences, Inc. (NASDAQ:SELB) (Simply Wall St.)
Mar-27-23 07:07AM	Is Selecta Biosciences, Inc.'s (NASDAQ:SELB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? (Simply Wall St.) -5.67%
Mar-21-23 11:48AM	Selecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year (Benzinga)
03:30AM	Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint (GlobeNewswire)
Mar-06-23 05:59AM	Selecta Biosciences, Inc. (NASDAQ:SELB) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-03-23 01:24AM	Q4 2022 Selecta Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-02-23 09:25AM	Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-23-23 08:00AM	Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update (GlobeNewswire)
Feb-07-23 01:51PM	The 7 Best Biotech Stocks to Buy for February 2023 (InvestorPlace)
08:00AM	Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-31-23 01:15PM	Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts (Benzinga)
Jan-17-23 11:33AM	Positive week for Selecta Biosciences, Inc. (NASDAQ:SELB) institutional investors who lost 34% over the past year (Simply Wall St.)
Jan-12-23 05:39AM	The Petri Dish: Moderna looks at new price tag for Covid vaccine (American City Business Journals) +5.44%
Jan-09-23 08:00AM	Selecta Biosciences Provides Business Update and Outlook for 2023 (GlobeNewswire) +8.13%
07:30AM	Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease (PR Newswire)
Dec-21-22 10:29AM	Shareholders in Selecta Biosciences (NASDAQ:SELB) have lost 89%, as stock drops 19% this past week (Simply Wall St.)
Dec-14-22 08:00AM	Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program (GlobeNewswire)
Dec-01-22 05:43AM	The Petri Dish: bluebird gets $102M; BMS vet joins Selecta's C-suite (American City Business Journals)
Nov-28-22 08:00AM	Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer (GlobeNewswire)
Nov-09-22 06:36AM	Selecta Biosciences Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) -8.39%
Nov-07-22 08:00AM	Selecta Biosciences to Participate at the Guggenheim Healthcare Talks \| 4th Annual Immunology & Neurology Day (GlobeNewswire)

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
English Emily	Chief Operations Officer	Apr 15 '25	Option Exercise	3.30	7,500	24,750	47,726	Apr 16 04:35 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	10.47	48,595	508,751	620,175	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	9.43	41,782	393,947	571,580	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	10.77	36,338	391,455	656,513	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	10.47	8,575	89,773	8,637,273	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	9.43	7,373	69,517	8,628,698	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	10.77	6,412	69,074	8,643,685	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Mar 20 '25	Buy	15.59	54,889	855,593	8,621,325	Mar 20 07:50 PM
SPRINGER TIMOTHY A	Director	Mar 19 '25	Buy	14.97	20,234	302,962	8,566,436	Mar 20 07:50 PM
SPRINGER TIMOTHY A	Director	Mar 18 '25	Buy	14.42	14,740	212,599	8,546,202	Mar 20 07:50 PM
SPRINGER TIMOTHY A	Director	Jan 13 '25	Buy	17.35	16,945	293,958	8,527,440	Jan 15 04:08 PM
SPRINGER TIMOTHY A	Director	Jan 14 '25	Buy	18.00	4,022	72,396	8,531,462	Jan 15 04:08 PM
Jewell Christopher M	Chief Scientific Officer	Jan 10 '25	Option Exercise	3.23	9,000	29,070	62,490	Jan 13 04:09 PM
Kurtoglu Metin	Chief Technology Officer	Jan 06 '25	Sale	16.83	2,458	41,374	62,258	Jan 07 08:05 PM
Kurtoglu Metin	Chief Technology Officer	Jan 03 '25	Sale	16.72	2,417	40,417	64,716	Jan 07 08:05 PM
Miljkovic Milos	Chief Medical Officer	Jan 06 '25	Sale	16.83	948	15,957	35,393	Jan 07 08:05 PM
Miljkovic Milos	Chief Medical Officer	Jan 03 '25	Sale	16.72	932	15,585	36,341	Jan 07 08:05 PM
Jewell Christopher M	Chief Scientific Officer	Jan 06 '25	Sale	16.83	1,286	21,646	53,490	Jan 07 08:05 PM
Jewell Christopher M	Chief Scientific Officer	Jan 03 '25	Sale	16.72	1,264	21,136	54,776	Jan 07 08:05 PM
English Emily	Chief Operations Officer	Jan 06 '25	Sale	16.83	906	15,250	40,226	Jan 07 08:05 PM
English Emily	Chief Operations Officer	Jan 03 '25	Sale	16.72	891	14,899	41,132	Jan 07 08:05 PM
Brunn Carsten	President and CEO	Jan 06 '25	Sale	16.83	8,708	146,575	204,096	Jan 07 08:04 PM
Brunn Carsten	President and CEO	Jan 03 '25	Sale	16.72	8,563	143,190	212,804	Jan 07 08:04 PM
Davis Blaine	Chief Financial Officer	Jan 06 '25	Sale	16.83	4,028	67,800	94,811	Jan 07 08:04 PM
Davis Blaine	Chief Financial Officer	Jan 03 '25	Sale	16.72	3,961	66,235	98,839	Jan 07 08:04 PM
English Emily	SVP, Head of Manufacturing	Dec 26 '24	Option Exercise	3.30	7,650	25,245	25,923	Dec 30 04:11 PM
SPRINGER TIMOTHY A	Director	Dec 19 '24	Buy	17.99	25,208	453,616	8,480,914	Dec 23 05:20 PM
SPRINGER TIMOTHY A	Director	Dec 20 '24	Buy	18.94	21,800	412,968	8,502,714	Dec 23 05:20 PM
SPRINGER TIMOTHY A	Director	Dec 23 '24	Buy	19.00	5,181	98,437	8,507,895	Dec 23 05:20 PM
Kurtoglu Metin	Chief Technology Officer	Dec 09 '24	Option Exercise	1.41	10,763	15,176	61,796	Dec 11 04:28 PM
Kurtoglu Metin	Chief Technology Officer	Dec 10 '24	Option Exercise	1.41	2,901	4,090	53,934	Dec 11 04:28 PM
Kurtoglu Metin	Chief Technology Officer	Dec 09 '24	Sale	25.50	10,763	274,494	51,033	Dec 11 04:28 PM
Kurtoglu Metin	Chief Technology Officer	Dec 10 '24	Sale	24.35	2,901	70,640	51,033	Dec 11 04:28 PM
METIN KURTOGLU	Officer	Dec 10 '24	Proposed Sale	24.35	2,901	70,640		Dec 10 04:21 PM
METIN KURTOGLU	Officer	Dec 09 '24	Proposed Sale	25.50	10,763	274,493		Dec 09 04:36 PM
Kurtoglu Metin	Chief Technology Officer	Nov 21 '24	Option Exercise	1.41	32,789	46,232	83,822	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 20 '24	Option Exercise	1.41	5,700	8,037	56,733	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 19 '24	Option Exercise	1.41	200	282	51,233	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 21 '24	Sale	16.67	32,789	546,560	51,033	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 20 '24	Sale	17.29	5,700	98,570	51,033	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 19 '24	Sale	19.50	200	3,900	51,033	Nov 21 06:52 PM
Jewell Christopher M	Chief Scientific Officer	Nov 20 '24	Option Exercise	3.23	14,000	45,220	39,940	Nov 21 06:50 PM
METIN KURTOGLU	Officer	Nov 21 '24	Proposed Sale	16.67	32,789	546,560		Nov 21 04:45 PM
METIN KURTOGLU	Officer	Nov 20 '24	Proposed Sale	17.29	5,700	98,570		Nov 20 04:57 PM
METIN KURTOGLU	Officer	Nov 19 '24	Proposed Sale	19.50	200	3,900		Nov 19 04:36 PM
SPRINGER TIMOTHY A	Director	Nov 15 '24	Buy	17.09	277,246	4,739,188	8,397,411	Nov 18 07:35 PM
SPRINGER TIMOTHY A	Director	Nov 14 '24	Buy	16.37	96,399	1,578,156	8,120,165	Nov 18 07:35 PM
SPRINGER TIMOTHY A	Director	Nov 18 '24	Buy	18.12	58,295	1,056,183	8,455,706	Nov 18 07:35 PM
Kurtoglu Metin	Chief Technology Officer	Nov 18 '24	Option Exercise	1.41	34,400	48,504	85,433	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 14 '24	Option Exercise	1.41	25,900	36,519	76,933	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 15 '24	Option Exercise	1.41	22,068	31,116	73,101	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 18 '24	Sale	18.39	34,400	632,641	51,033	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 14 '24	Sale	16.44	25,900	425,900	51,033	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 15 '24	Sale	17.20	22,068	379,497	51,033	Nov 18 07:32 PM
Miljkovic Milos	Chief Medical Officer	Nov 14 '24	Option Exercise	3.23	35,000	113,050	53,273	Nov 18 07:28 PM
Miljkovic Milos	Chief Medical Officer	Nov 15 '24	Option Exercise	3.23	20,000	64,600	38,273	Nov 18 07:28 PM
Miljkovic Milos	Chief Medical Officer	Nov 14 '24	Sale	16.13	35,000	564,644	18,273	Nov 18 07:28 PM
Miljkovic Milos	Chief Medical Officer	Nov 15 '24	Sale	17.14	20,000	342,888	18,273	Nov 18 07:28 PM
Jewell Christopher M	Chief Scientific Officer	Nov 14 '24	Option Exercise	3.23	36,050	116,442	61,990	Nov 18 07:23 PM
Jewell Christopher M	Chief Scientific Officer	Nov 15 '24	Option Exercise	3.23	16,065	51,890	42,005	Nov 18 07:23 PM
Jewell Christopher M	Chief Scientific Officer	Nov 14 '24	Sale	16.67	36,050	600,949	25,940	Nov 18 07:23 PM
Jewell Christopher M	Chief Scientific Officer	Nov 15 '24	Sale	17.06	16,065	274,093	25,940	Nov 18 07:23 PM
METIN KURTOGLU	Officer	Nov 18 '24	Proposed Sale	18.39	34,400	632,640		Nov 18 04:24 PM
METIN KURTOGLU	Officer	Nov 15 '24	Proposed Sale	17.20	22,068	379,497		Nov 15 05:07 PM
CHRISTOPHER M JEWELL	Officer	Nov 15 '24	Proposed Sale	17.06	16,065	274,093		Nov 15 04:57 PM
MILOS MILJKOVIC	Officer	Nov 15 '24	Proposed Sale	17.14	20,000	342,889		Nov 15 04:44 PM
METIN KURTOGLU	Officer	Nov 14 '24	Proposed Sale	16.44	25,900	425,900		Nov 14 05:30 PM
CHRISTOPHER M JEWELL	Officer	Nov 14 '24	Proposed Sale	16.67	36,050	600,949		Nov 14 05:29 PM
MILOS MILJKOVIC	Officer	Nov 14 '24	Proposed Sale	16.13	35,000	564,644		Nov 14 05:13 PM
SPRINGER TIMOTHY A	Director	Oct 03 '24	Buy	19.89	119,906	2,384,713	7,943,465	Oct 04 05:58 PM
SPRINGER TIMOTHY A	Director	Oct 04 '24	Buy	22.58	80,301	1,813,010	8,023,766	Oct 04 05:58 PM
SPRINGER TIMOTHY A	Director	Oct 02 '24	Buy	17.38	5,514	95,822	7,823,559	Oct 04 05:58 PM
SPRINGER TIMOTHY A	Director	Aug 12 '24	Buy	12.72	8,016	101,968	11,509	Aug 14 04:43 PM
BARABE TIMOTHY C	Director	Aug 12 '24	Buy	12.70	7,500	95,250	21,766	Aug 14 04:41 PM

TECX

Tectonic Therapeutic Inc

RNAC

Cartesian Therapeutics Inc

Upgrade your FINVIZ experience